This week in Part 3 of our Case Study, Mr. Walker and his wife return for a follow-up visit as his glucose control has not improved as much as expected. Click here to see if you agree with the drug choice.
In our analysis of the GLP-1 survey data, we take a look at some of your perceptions of GLP-1 Agonists, how they work, and what you think about the side effects and DPP-4 inhibitors.
In addition, Steve and our team of interns have found some late breaking abstracts on GLP-1 agonists from the ADA that you probably won’t see anywhere else. And we’ve included a special feature this week on the Effect of Glp-1 on Cardiovascular Risk Factors.